{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:46:38Z","timestamp":1788518798399,"version":"build-2803163510"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.critrevonc.2023.104225","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T21:11:05Z","timestamp":1701551465000},"page":"104225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape"],"prefix":"10.1016","volume":"193","author":[{"given":"Sara","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrina","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Khojasteh-Kaffash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parya","family":"Valizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noosha","family":"Samieefar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the Immune System: The History and Background of Immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin Oncol. Nurs."},{"key":"10.1016\/j.critrevonc.2023.104225_bib2","unstructured":"Academic, Community Cancer Research U., National Cancer I. Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma 2019 [updated August 13. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02758717\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/cancers13050989","article-title":"Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not?","volume":"13","author":"Albandar","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib4","first-page":"139","article-title":"Pediatric lymphomas and histiocytic disorders of childhood","volume":"62","author":"Allen","year":"2015","journal-title":"Pediatr. Clin."},{"key":"10.1016\/j.critrevonc.2023.104225_bib5","doi-asserted-by":"crossref","unstructured":"Allison J., Krummel M., Leach D. Enhancement of Antitumor Immunity by CTLA-4 Blockade. science.271:1734.","DOI":"10.1126\/science.271.5256.1734"},{"key":"10.1016\/j.critrevonc.2023.104225_bib6","unstructured":"American Society of Clinical O., Astra Zeneca, Bayer, Bristol-Myers S., Eli L., Company, et al. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer 2024 [updated December 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02693535\u3009."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/pbc.26018","article-title":"Low frequency of programmed death ligand 1 expression in pediatric cancers","volume":"63","author":"Aoki","year":"2016","journal-title":"Pediatr. blood Cancer"},{"issue":"33","key":"10.1016\/j.critrevonc.2023.104225_bib10","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2023.104225_bib11","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib12","unstructured":"AstraZeneca. Durvalumab and Tremelimumab for Pediatric Malignancies 2023 [updated February 28. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03837899\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib13","unstructured":"Baylor College of M., The Methodist Hospital Research I, Center for C, Gene Therapy BCoM. CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL 2014 [updated July. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT00586391\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib14","unstructured":"Baylor College of M., The Methodist Hospital Research I., Center for C., Gene Therapy B.Co.M. Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed\/Refractory EBV Positive Lymphoma (PREVALE) 2019 [updated September 5. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02973113\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101445","article-title":"Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults","author":"Belsky","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib16","series-title":"Seminars in oncology","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","year":"2010"},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104225_bib17","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib18","unstructured":"Bristol-Myers S. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma 2028 [updated July 5. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05255601\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib19","article-title":"A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children","author":"Bristol-Myers","year":"2022","journal-title":"Adolesc. Young-.-. Adults Recurr. Or. Treat. -Resist. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104225_bib20","unstructured":"Bristol-Myers S., Seagen I. An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas 2020 [updated January 16. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02581631\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib21","unstructured":"Bristol-Myers S., Seagen I. A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment 2024 [updated January 8. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02927769\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101748","article-title":"Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma","author":"Brown","year":"2022","journal-title":"Surg. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104225_bib23","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-Mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104225_bib24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1542\/pir.2016-0152","article-title":"Pediatric Lymphoma","volume":"38","author":"Buhtoiarov","year":"2017","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.critrevonc.2023.104225_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2219","article-title":"Management of paediatric and adult non\u2010Hodgkin lymphoma: what lessons can each teach the other?","volume":"33","author":"Burkhardt","year":"2015","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjh.15764","article-title":"Childhood, adolescent and young adult non\u2010Hodgkin lymphoma: current perspectives","volume":"185","author":"Cairo","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.14035","article-title":"Childhood, adolescent and young adult non\u2010Hodgkin lymphoma: state of the science","volume":"173","author":"Cairo","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","article-title":"Burkitt's and Burkitt\u2010like lymphoma in children and adolescents: a review of the Children's Cancer Group experience","volume":"120","author":"Cairo","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104225_bib29","first-page":"5019","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104225_bib30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-19-0692","article-title":"Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies","volume":"8","author":"Casey","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2023.104225_bib32","unstructured":"Catherine B., Children's National Research I. Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma 2023 [updated May. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03843294\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib33","unstructured":"Center M.D.A.C. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed\/Refractory Hodgkin's Lymphoma 2026 [updated December 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05355051\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00431-017-2982-0","article-title":"Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot","volume":"176","author":"Ceppi","year":"2017","journal-title":"Eur. J. Pediatr."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biomedicines6010014","article-title":"Bringing the next generation of immuno-oncology biomarkers to the clinic","volume":"6","author":"Cesano","year":"2018","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104225_bib36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib37","first-page":"869","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaci.2014.10.019","article-title":"Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA","volume":"135","author":"Charbonnier","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2023.104225_bib40","unstructured":"Chen L., Wang M., Fan H., Hu F., Liu T. Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104225_bib41","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib42","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-8-2","article-title":"Tumor lysis syndrome in childhood malignancies","volume":"9","author":"Cheung","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.critrevonc.2023.104225_bib43","unstructured":"Children's Hospital Los A. Durvalumab in Pediatric and Adolescent Patients 2019 [updated December. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02793466\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib44","unstructured":"Children's Hospital Medical Center C. Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults 2024 [updated June 15. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03445858\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib45","unstructured":"Chinese P.L.A.G.H. Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R\/R NHL and Advanced Solid Tumors 2024 [updated April 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05320640\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib46","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"key":"10.1016\/j.critrevonc.2023.104225_bib47","unstructured":"City of Hope Medical C., National Cancer I. Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma 2023 [updated August 23. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03712202\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib48","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S2152-2650(20)30835-1","volume":"20","author":"Cole","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib49","article-title":"Hodgkin lymphoma (Primer)","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev.: Dis. Prim."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104225_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11952","article-title":"Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non\u2013small cell lung cancer in the United States","volume":"2","author":"Criss","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"24","key":"10.1016\/j.critrevonc.2023.104225_bib51","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: National cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"issue":"6\u20137","key":"10.1016\/j.critrevonc.2023.104225_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/08880018.2017.1383542","article-title":"Checkpoint inhibition in pediatric hematologic malignancies","volume":"34","author":"Davis","year":"2017","journal-title":"Pedia Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104225_bib54","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children's Oncology Group Study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104225_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.965803","article-title":"Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma","volume":"10","author":"De Re","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib56","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/cancers14061569","article-title":"The new treatment methods for non-hodgkin lymphoma in pediatric patients","volume":"14","author":"Derebas","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2023.104225_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X221090156","article-title":"Non Hodgkin Lymphoma Among Children: Pathological Aspects and Diagnostic Challenges","volume":"15","author":"Derqaoui","year":"2022","journal-title":"Clin. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104225_bib58","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/awu230","article-title":"Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia","volume":"137","author":"Edelmann","year":"2014","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1074-7613(01)00259-X","article-title":"Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength","volume":"16","author":"Egen","year":"2002","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib60","first-page":"113","article-title":"Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma","volume":"13","author":"El-Mallawany","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib61","unstructured":"Emory U., National Cancer I. Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed\/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors 2026 [updated November 30. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05039073\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","article-title":"Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers","volume":"55","author":"Eso","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","article-title":"Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer","volume":"81","author":"Falvo","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib64","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/MPH.0000000000000703","article-title":"Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma","volume":"39","author":"Foran","year":"2017","journal-title":"J. Pediatr. Hematol. \/Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib65","article-title":"Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk","volume":"4","author":"Franklin","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20081811","article-title":"CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance","volume":"206","author":"Friedline","year":"2009","journal-title":"J. Exp. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib67","first-page":"473","article-title":"T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer","volume":"10","author":"Fu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104225_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib71","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-18-0836","article-title":"TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In VivoAnti-LAG-3 Synergy with PD-1 Blockade in Mouse Tumor Models","volume":"18","author":"Ghosh","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib72","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1402382","article-title":"Elevation of c-MYC disrupts HLA class II\u2013mediated immune recognition of human B cell tumors","volume":"194","author":"God","year":"2015","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib73","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.anai.2021.03.003","article-title":"Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy","volume":"126","author":"Goleva","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104225_bib74","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14656566.2019.1606212","article-title":"Treatment of classical Hodgkin's lymphoma in children and adolescents","volume":"20","author":"G\u00f3mez-Almaguer","year":"2019","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104225_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02100","article-title":"The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent","volume":"9","author":"Grasselly","year":"2018","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104225_bib76","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.3138","article-title":"Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: An IMPACT Cohort Study","volume":"9","author":"Gupta","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib77","unstructured":"Gustave Roussy C.C.G.P. Nivolumab for Pediatric and Adult Relapsing\/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) 2023 [updated June. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03703050\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib78","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/clpt.2014.74","article-title":"Immunologic and clinical effects of targeting PD\u20101 in lung cancer","volume":"96","author":"Harvey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104225_bib79","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104225_bib80","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"Lymphocyte\u2010activation gene\u20103, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib81","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann. Intern Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ctrv.2005.04.011","article-title":"Hodgkin Lymphoma in adolescents","volume":"31","author":"Herbertson","year":"2005","journal-title":"Cancer Treat. Rev."},{"issue":"7528","key":"10.1016\/j.critrevonc.2023.104225_bib83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib84","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib85","unstructured":"Hoffmann-La R. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors 2019 [updated June 6. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02541604\u3009."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib86","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib87","unstructured":"Hospital Regional de Alta Especialidad del B., Universidad de G. Treatment Strategy for Relapsed\/Refractory Hodgkin Lymphoma 2024 [updated October 18. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05595447\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib88","unstructured":"Hospital Universitario Dr Jose E.G. Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma 2024 [updated March 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05772624\u3009."},{"issue":"6332","key":"10.1016\/j.critrevonc.2023.104225_bib89","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib90","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1297\/cpe.28.59","article-title":"Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events","volume":"28","author":"Ihara","year":"2019","journal-title":"Clin. Pedia Endocrinol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib91","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12098-013-1128-2","article-title":"Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics","volume":"80","author":"Iyer","year":"2013","journal-title":"Indian J. Pediatr."},{"issue":"6332","key":"10.1016\/j.critrevonc.2023.104225_bib92","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"issue":"10111","key":"10.1016\/j.critrevonc.2023.104225_bib93","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08975.x","article-title":"Management of children with high\u2010risk Hodgkin lymphoma","volume":"157","author":"Kelly","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104225_bib95","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.critrevonc.2023.104225_bib96","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011936","article-title":"Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials","volume":"97","author":"Khan","year":"2018","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pin.12259","article-title":"Role of tumor\u2010associated macrophages in hematological malignancies","volume":"65","author":"Komohara","year":"2015","journal-title":"Pathol. Int."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.18620\/ctt-1866-8836-2019-8-4-41-48","article-title":"Nivolumab in pediatric Hodgkin's lymphoma","volume":"8","author":"Kozlov","year":"2019","journal-title":"Cell. Ther. Transplant."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104225_bib100","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.3390\/ijms21155456","article-title":"Immune-checkpoint blockade therapy in lymphoma","volume":"21","author":"Kuzume","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104225_bib101","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104225_bib103","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6349","key":"10.1016\/j.critrevonc.2023.104225_bib104","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2023.104225_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100644","article-title":"Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer","volume":"46","author":"Leonetti","year":"2019","journal-title":"Drug Resist. Updates"},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104225_bib106","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104225_bib107","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib108","series-title":"Pathogenesis and Pathology of Pediatric Lymphoma","first-page":"1","author":"Li","year":"2021"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0031-3955(16)34832-5","article-title":"Non-Hodgkin\u2019s lymphoma in children","volume":"32","author":"Link","year":"1985","journal-title":"Pediatr. Clin. North Am."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104225_bib110","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6246","key":"10.1016\/j.critrevonc.2023.104225_bib113","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104225_bib114","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00262-022-03159-8","article-title":"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1\/2 trial","volume":"71","author":"Loeb","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"42","key":"10.1016\/j.critrevonc.2023.104225_bib115","first-page":"1","article-title":"Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again","author":"Long","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104225_bib116","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.30724","article-title":"Assessment of programmed death\u2010ligand 1 expression and tumor\u2010associated immune cells in pediatric cancer tissues","volume":"123","author":"Majzner","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104225_bib117","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.21873\/anticanres.14738","article-title":"Nivolumab for the Treatment of Advanced Pediatric Malignancies","volume":"40","author":"MarjaNska","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2023.104225_bib118","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz427.018","article-title":"Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667","volume":"30","author":"Mauz-koerholz","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40272-017-0265-x","article-title":"Pharmacotherapeutic management of pediatric lymphoma","volume":"20","author":"Mauz-K\u00f6rholz","year":"2018","journal-title":"Pediatr. Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/joim.13395","article-title":"Advances in immune therapies in hematological malignancies","volume":"292","author":"Mazzarella","year":"2022","journal-title":"J. Intern Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib121","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.104225_bib122","unstructured":"Merck S., Dohme L.L.C. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475\u2013051\/KEYNOTE-051) 2025 [updated May 6. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02332668\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib123","unstructured":"Merck S., Dohme L.L.C. Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475\u2013667\/KEYNOTE-667) 2027 [updated February 13. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03407144\u3009."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib124","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.critrevonc.2023.104225_bib125","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib126","unstructured":"Mingzhi Z., Zhengzhou U. Treatment of Relapsed or Refractory Natural Killer\/T Cell Lymphoma 2018 [updated December. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03107962\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2019.04.025","article-title":"PD-1\/PD-L1 blockade in paediatric cancers: What does the future hold?","volume":"457","author":"Moreno-Vicente","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2023.104225_bib128","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00234-013-1245-7","article-title":"Effects of chemotherapy on the brain in childhood: diffusion tensor imaging of subtle white matter damage","volume":"55","author":"Morioka","year":"2013","journal-title":"Neuroradiology"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib129","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib131","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2023.104225_bib132","unstructured":"National Cancer I. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab 2030 [updated June 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05675410\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib133","unstructured":"National Cancer I., National Institutes of Health Clinical C. Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer 2014 [updated April 18. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT01445379\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib134","unstructured":"National Cancer I. Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas 2021 [updated September 30. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02304458\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib135","unstructured":"National Cancer I. Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S\u00e9zary Syndrome and Advanced Synovial Sarcoma 2021 [updated April 8. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03063632\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib136","unstructured":"National Cancer I. Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma 2024 [updated March 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03907488\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib137","unstructured":"National Cancer I. Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma 2025 [updated March 20. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT01896999\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib138","unstructured":"National Cancer I. A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed\/Refractory Classical Hodgkin Lymphoma 2028 [updated June 30. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05711628\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib139","unstructured":"National Cancer I. Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma 2028 [updated December 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04759586\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib140","unstructured":"National Cancer I., National Institutes of Health Clinical C. Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas 2029 [updated June 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03258567\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib141","unstructured":"New York Medical C. Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma 2027 [updated December 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05253495\u3009."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib142","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib143","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem"},{"key":"10.1016\/j.critrevonc.2023.104225_bib144","series-title":"Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy","first-page":"276","author":"Nigro","year":"2021"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib145","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/03008916211010214","article-title":"Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy","volume":"107","author":"Nigro","year":"2021","journal-title":"Tumori"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib146","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104225_bib147","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib148","doi-asserted-by":"crossref","first-page":"129","DOI":"10.17219\/acem\/142535","article-title":"Effect of thiamine pyrophosphate on cyclophosphamide-induced oxidative ovarian damage and reproductive dysfunction in female rats","volume":"31","author":"Ozer","year":"2022","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","article-title":"Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies","volume":"58","author":"Park","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2023.104225_bib151","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib152","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib153","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","article-title":"B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse","volume":"21","author":"Pentcheva-Hoang","year":"2004","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib154","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/biom10071061","article-title":"Epigenetic mechanisms of resistance to immune checkpoint inhibitors","volume":"10","author":"Perrier","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2023.104225_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2023.104225_bib156","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib157","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaLong-term Follow-up of Melanoma Patients Treated with Ipilimumab","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104225_bib158","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-19-2959","article-title":"Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination ImmunotherapyGemcitabine Primes Pancreatic Cancer for Immunotherapy","volume":"80","author":"Principe","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104225_bib159","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-9-2","article-title":"Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1\/PD-L1 therapies","volume":"9","author":"Puri","year":"2020","journal-title":"Drugs Context"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1667\/RR15048.1","article-title":"Complete local and Abscopal responses from a combination of radiation and Nivolumab in refractory Hodgkin's lymphoma","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib161","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canrad.2018.05.002","article-title":"Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma","volume":"23","author":"Qu\u00e9ro","year":"2019","journal-title":"Cancer\/Radio."},{"issue":"6029","key":"10.1016\/j.critrevonc.2023.104225_bib162","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104225_bib163","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-14","article-title":"Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer","volume":"2","author":"Raval","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104225_bib165","unstructured":"Research E.M.D.S., Development Institute I., Merck KgaA D.G., Serono E.M.D. Phase I\/II Study of Avelumab in Pediatric Cancer Subjects 2021 [updated July 27. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03451825\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib166","series-title":"Seminars in oncology","article-title":"Clinical development of the anti\u2013CTLA-4 antibody tremelimumab","year":"2010"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib167","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pedia Blood Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104225_bib168","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104225_bib169","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104225_bib170","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104225_bib171","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1289\/ehp.10596","article-title":"Household exposure to pesticides and risk of childhood hematopoietic malignancies: the ESCALE study (SFCE)","volume":"115","author":"Rudant","year":"2007","journal-title":"Environ. Health Perspect."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib172","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0360-3016(01)01798-9","article-title":"Response-adapted radiotherapy in the treatment of pediatric Hodgkin\u2019s disease: an interim report at 5 years of the German GPOH-HD 95 trial","volume":"51","author":"R\u00fchl","year":"2001","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib173","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib174","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-3083.2009.02355.x","article-title":"Combination of CTL\u2010associated Antigen\u20104 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell\u2010based Vaccine in a Mouse Model of Colon Cancer","volume":"71","author":"Saha","year":"2010","journal-title":"Scand. J. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104225_bib175","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib176","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib177","first-page":"397","article-title":"The value of immunotherapy in pediatric leukemia and lymphoma","volume":"14","author":"Salzer","year":"2021","journal-title":"Memo. - Mag. Eur. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib178","unstructured":"Sanofi, Merck S., Dohme L.L.C. A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) Pegathor Lymphoma 205 2023 [updated September 14. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05179603\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib179","unstructured":"Sarcoma Oncology Research Center L.L.C., Aadi Bioscience I. Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers 2021 [updated December 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03190174\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib180","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29288","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer","volume":"3","author":"Schalper","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2023.104225_bib181","unstructured":"Seagen I., Bristol-Myers S. Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma 2022 [updated November 7. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03646123\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib182","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211036526","article-title":"Immune Checkpoint Inhibitors in Special Populations","volume":"20","author":"Shan","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104225_bib183","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000670","article-title":"Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country","volume":"94","author":"Sherief","year":"2015","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib184","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.molcel.2019.12.012","article-title":"PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation","volume":"77","author":"Shimizu","year":"2020","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2040620718761777","article-title":"Pembrolizumab and its role in relapsed\/refractory classical Hodgkin\u2019s lymphoma: evidence to date and clinical utility","volume":"9","author":"Shindiapina","year":"2018","journal-title":"Ther. Adv. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104672","article-title":"An update on molecular features and therapeutic perspectives of pediatric classical Hodgkin Lymphoma. What the clinician needs to know?","volume":"66","author":"Simonin","year":"2023","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.critrevonc.2023.104225_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.855725","article-title":"Advances in Hodgkin Lymphoma: Including the Patient's Voice","volume":"12","author":"Smith","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib188","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6440","key":"10.1016\/j.critrevonc.2023.104225_bib189","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2023.104225_bib190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2016.00233","article-title":"Combination approaches with immune-checkpoint blockade in cancer therapy","volume":"6","author":"Swart","year":"2016","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib191","unstructured":"Tessa T., Bristol-Myers S. Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy 2025 [updated December 15. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05352828\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib192","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14151","article-title":"Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)","author":"Thapa","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104225_bib193","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0009-9260(97)80253-X","article-title":"Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids","volume":"52","author":"Thornton","year":"1997","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib194","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-1115-8_1","article-title":"A brief outline of the immune system","author":"Tomar","year":"2014","journal-title":"Immunoinformatics"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104225_bib195","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104225_bib196","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/OTT.S48443","article-title":"PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence","author":"Tykodi","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.critrevonc.2023.104225_bib197","unstructured":"Unicancer, National Cancer Institute F., Ligue contre le cancer F., Merck S., Dohme L.L.C. Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types 2022 [updated December 26. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03012620\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib198","unstructured":"University College L., Bristol-Myers S. ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed\/Refractory Hodgkin Lymphoma 2023 [updated March 1. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03337919\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib199","unstructured":"University College L., Pfizer. Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study 2022 [updated July 4. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03617666\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib200","unstructured":"University Hospital Southampton N.H.S.F.T., Hoffmann-La R. Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy 2021 [updated January 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03422523\u3009."},{"key":"10.1016\/j.critrevonc.2023.104225_bib201","unstructured":"University of B., Bloodwise, Pfizer. Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma 2020 [updated July 31. Available from: \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03046953\u3009."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib202","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J. Exp. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"Van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/1097-0215(20000815)87:4<539::AID-IJC13>3.0.CO;2-E","article-title":"B7\u20131, IFN\u03b3 and anti\u2010CTLA\u20104 co\u2010operate to prevent T\u2010cell tolerization during immunotherapy against a murine T\u2010lymphoma","volume":"87","author":"Van Ginderachter","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-16-0037","article-title":"Toward Precision Radiotherapy for Use with Immune Checkpoint BlockersPredicting and Optimizing Radiation-Driven Immune Responses","volume":"24","author":"Vanpouille-Box","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib207","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40262-022-01111-8","article-title":"Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors","volume":"61","author":"Vugmeyster","year":"2022","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib208","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5476","article-title":"Challenges for Measuring Cost-effectiveness of Immunotherapy in Unresectable Hepatocellular Carcinoma","volume":"4","author":"Wagle","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104225_bib209","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7555\/JBR.31.20160168","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"32","author":"Webb","year":"2018","journal-title":"J. Biomed. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104225_bib211","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104225_bib212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","article-title":"Pediatric cancer immunotherapy: opportunities and challenges","volume":"20","author":"Wedekind","year":"2018","journal-title":"Pediatr. Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104225_bib213","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","article-title":"Pediatric Cancer Immunotherapy: Opportunities and Challenges","volume":"20","author":"Wedekind","year":"2018","journal-title":"Paediatr. Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib214","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/1040-8428(92)90016-J","article-title":"Non-Hodgkin's lymphomas in children. I. Patterns of disease and classification","volume":"13","author":"White","year":"1992","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"7455","key":"10.1016\/j.critrevonc.2023.104225_bib216","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/498S10a","article-title":"Epigenetics: reversible tags","volume":"498","author":"Wright","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2023.104225_bib217","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2023.104225_bib218","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01739","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104225_bib219","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104225_bib220","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201906922","article-title":"In situ formed fibrin scaffold with cyclophosphamide to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib221","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","article-title":"Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104225_bib222","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib223","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104225_bib224","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104225_bib225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41419-021-03499-w","article-title":"Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy","volume":"12","author":"Zuo","year":"2021","journal-title":"Cell death Dis."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282300313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282300313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:52:48Z","timestamp":1760903568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282300313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":225,"alternative-id":["S104084282300313X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104225","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104225"}}